Hims & Hers Health Inc (NYSE: HIMS) has a price-to-earnings ratio of 72.01x that is above its average ratio. Additionally, the 36-month beta value for HIMS is 1.88. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 rating it as “hold,” and 1 rating it as “sell.”
The public float for HIMS is 183.36M and currently, short sellers hold a 33.08% ratio of that float. The average trading volume of HIMS on May 07, 2025 was 30.58M shares.
HIMS) stock’s latest price update
The stock price of Hims & Hers Health Inc (NYSE: HIMS) has surged by 18.12 when compared to previous closing price of 41.88, but the company has seen a 41.18% gain in its stock price over the last five trading sessions. fool.com reported 2025-05-06 that Investors are buying Hims & Hers Health (HIMS 19.77%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they’re selling off shares of Eli Lilly (LLY -6.21%) and Novo Nordisk (NVO -4.31%), the latter of which is a Hims & Hers partner now.
HIMS’s Market Performance
HIMS’s stock has risen by 41.18% in the past week, with a monthly rise of 90.34% and a quarterly rise of 18.21%. The volatility ratio for the week is 14.83% while the volatility levels for the last 30 days are 11.76% for Hims & Hers Health Inc The simple moving average for the past 20 days is 59.41% for HIMS’s stock, with a 81.59% simple moving average for the past 200 days.
Analysts’ Opinion of HIMS
Many brokerage firms have already submitted their reports for HIMS stocks, with TD Cowen repeating the rating for HIMS by listing it as a “Hold.” The predicted price for HIMS in the upcoming period, according to TD Cowen is $30 based on the research report published on April 29, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see HIMS reach a price target of $60, previously predicting the price at $42. The rating they have provided for HIMS stocks is “Equal-Weight” according to the report published on February 18th, 2025.
Citigroup gave a rating of “Sell” to HIMS, setting the target price at $25 in the report published on January 10th of the current year.
HIMS Trading at 49.08% from the 50-Day Moving Average
After a stumble in the market that brought HIMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.21% of loss for the given period.
Volatility was left at 11.76%, however, over the last 30 days, the volatility rate increased by 14.83%, as shares surge +78.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.59% lower at present.
During the last 5 trading sessions, HIMS rose by +41.18%, which changed the moving average for the period of 200-days by +142.86% in comparison to the 20-day moving average, which settled at $31.03. In addition, Hims & Hers Health Inc saw 104.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HIMS starting from Boughton Soleil, who sale 3,236 shares at the price of $30.19 back on Apr 28 ’25. After this action, Boughton Soleil now owns 159,662 shares of Hims & Hers Health Inc, valued at $97,695 using the latest closing price.
Dudum Andrew, the Chief Executive Officer of Hims & Hers Health Inc, sale 50,000 shares at $36.39 during a trade that took place back on Apr 29 ’25, which means that Dudum Andrew is holding 92,103 shares at $1,819,310 based on the most recent closing price.
Stock Fundamentals for HIMS
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.75 for the gross margin
The net margin for Hims & Hers Health Inc stands at 0.09. The total capital return value is set at 0.18. Equity return is now at value 36.79, with 24.54 for asset returns.
Based on Hims & Hers Health Inc (HIMS), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 5.27.
Currently, EBITDA for the company is 78.99 million with net debt to EBITDA at -1.7. When we switch over and look at the enterprise to sales, we see a ratio of 5.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.59.
Conclusion
In conclusion, Hims & Hers Health Inc (HIMS) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
